Colorectal Cancer |
Colon and Rectal Cancer |
Clinical Trial: ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer
This study is currently recruiting patients.
|
Purpose
The purpose of this study is to determine that ABX-EGF will have clinically meaningful anti-tumor activity in patients with metastatic colorectal cancer who have developed progressive disease or relapsed while on or after prior fluoropyrimidine, irinotecan and oxaliplatin chemotherapy.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Colorectal Cancer Metastases | Drug: ABX-EGF | Phase II |
MedlinePlus related topics: Cancer; Cancer Alternative Therapy; Colorectal Cancer
Study Type: Interventional
Study Design: Treatment, Efficacy Study
Official Title: A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer Whose Tumors Express Low or Negative EGFr Levels of Immunohistochemistry Following Treatment with Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Pathologic diagnosis of colorectal adenocarcinoma (diagnostic tissue obtained by tissue biopsy)
- Metastatic colorectal carcinoma
- Eastern Cooperative Oncology Group of 0, 1 or 2
- Documented evidence of disease progression during, or following treatment, with fluoropyrimidine, irinotecan and oxaliplatin chemotherapy for metastatic colorectal cancer
- Radiographic documentation of disease progression during or within 6 months following the most recent chemotherapy regimen is required
- Bidimensionally measurable disease
- Tumor expressing low to negative levels of EGFr by immunohistochemistry
- At least 2 but no more than 3 prior chemotherapy regimens for metastatic colorectal cancer
- Adequate hematologic, renal and hepatic function
Exclusion Criteria:
- Symptomatic brain metastases requiring treatment
- Patient with a history of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis
- Use of systemic chemotherapy or radiotherapy within 30 days before enrollment
- Prior anti-EGFr antibody therapy with the exception of the small molecule EGFr tyrosine kinas inhibitors, which are permitted
- Prior anti-tumor therapies including prior experimental agents or approved anti-tumor small molecules and biologics of short (less than 1 week) serum half-life within 30 days before enrollment, or prior experimental or approved proteins within 6 weeks before enrollment
Location and Contact Information
Arizona
Research Center, Lake Havasu City, Arizona, United States; Recruiting
California
Research Site, Loma Linda, California, United States; Recruiting
Research Site, Redding, California, United States; Recruiting
Research Center, Burbank, California, United States; Recruiting
Research Center, Los Angeles, California, United States; Recruiting
Colorado
Research Site, Aurora, Colorado, United States; Recruiting
Research Site, Boulder, Colorado, United States; Recruiting
Research Site, Colorado Springs, Colorado, United States; Recruiting
Research Site, Denver, Colorado, United States; Recruiting
Research Center, Littleton, Colorado, United States; Recruiting
Connecticut
Research Site, Stamford, Connecticut, United States; Recruiting
Research Site, Waterbury, Connecticut, United States; Recruiting
Research Site, Norwich, Connecticut, United States; Recruiting
District of Columbia
Research Site, Washington, District of Columbia, United States; Recruiting
Florida
Research Site, Jacksonville, Florida, United States; Recruiting
Research Site, Orange Park, Florida, United States; Recruiting
Research Site, Stuart, Florida, United States; Recruiting
Georgia
Research Site, Atlanta, Georgia, United States; Recruiting
Research Site, Augusta, Georgia, United States; Recruiting
Idaho
Research Center, Boise, Idaho, United States; Recruiting
Illinois
Research Site, Chicago, Illinois, United States; Recruiting
Research Site, Harvey, Illinois, United States; Recruiting
Research Site, Libertyville, Illinois, United States; Recruiting
Research Site, Skokie, Illinois, United States; Recruiting
Indiana
Research Site, Noblesville, Indiana, United States; Recruiting
Research Site, Indianapolis, Indiana, United States; Recruiting
Research Site, New Albany, Indiana, United States; Recruiting
Kentucky
Research Site, Paducah, Kentucky, United States; Recruiting
Maryland
Research Center, Baltimore, Maryland, United States; Recruiting
Michigan
Research Site, Flint, Michigan, United States; Recruiting
Research Site, St. Joseph, Michigan, United States; Recruiting
Montana
Research Site, Billings, Montana, United States; Recruiting
Nevada
Research Center, Reno, Nevada, United States; Recruiting
New Mexico
Research Site, Santa Fe, New Mexico, United States; Recruiting
Research Center, Albuquerque, New Mexico, United States; Recruiting
New York
Research Site, Bronx, New York, United States; Recruiting
Research Site, New York, New York, United States; Recruiting
Research Center, Fresh Meadows, New York, United States; Recruiting
North Carolina
Research Site, Charlotte, North Carolina, United States; Recruiting
Ohio
Research Site, Canton, Ohio, United States; Recruiting
Research Site, Columbus, Ohio, United States; Recruiting
Research Site, Westerville, Ohio, United States; Recruiting
Oklahoma
Research Site, Oklahoma City, Oklahoma, United States; Recruiting
Pennsylvania
Research Site, Philadelphia, Pennsylvania, United States; Recruiting
Research Site, Pittsburgh, Pennsylvania, United States; Recruiting
South Carolina
Research Center, Charleston, South Carolina, United States; Recruiting
Research Center, Hilton Head, South Carolina, United States; Recruiting
Tennessee
Research Site, Collierville, Tennessee, United States; Recruiting
Research Site, Memphis, Tennessee, United States; Recruiting
Research Center, Nashville, Tennessee, United States; Recruiting
Texas
Research Site, Dallas, Texas, United States; Recruiting
Research Site, Lubbock, Texas, United States; Recruiting
Research Center, Amarillo, Texas, United States; Recruiting
Research Center, Austin, Texas, United States; Recruiting
Utah
Research Site, Ogden, Utah, United States; Recruiting
Research Site, Salt Lake City, Utah, United States; Recruiting
Virginia
Research Site, Abingdon, Virginia, United States; Recruiting
Wisconsin
Research Site, Madison, Wisconsin, United States; Recruiting
More Information
AmgenTrials clinical trials website
Center Watch Clinical Trials Listing Service
Record last reviewed: February 2005
Last Updated: February 11, 2005
Record first received: August 9, 2004
ClinicalTrials.gov Identifier: NCT00089635
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 8, 2005
Resources
- 6 Questions That Could Save Your Life (Or the Life of Someone You Love): What Women Need to Know about Colon Cancer Screening (American Society for Gastrointestinal Endoscopy)
- A Personal Perspective on Rectal Cancer (Cleveland Clinic)

Not Signed In -


